Skip to main content
Top
Published in: Breast Cancer 6/2014

Open Access 01-11-2014 | Special Feature

Fertility preservation in breast cancer patients

Authors: Tadahiko Shien, Mikiya Nakatsuka, Hiroyoshi Doihara

Published in: Breast Cancer | Issue 6/2014

Login to get access

Abstract

Systemic therapies have been shown to effectively improve prognosis in patients with breast cancer. However, such therapies also become increasingly harmful as their duration increases, and they have adverse effects on fertility and ovarian function. Fertility preservation (FP) is important in young adult cancer survivors who may wish to have children. In Japan, some cancer societies recommend that the potentially serious effects of systemic therapy on ovarian function should be explained to women with cancer, and they should be encouraged to undergo FP prior to commencing treatment. Still, as there are no official guidelines, many oncologists lack the required knowledge and mind-set to advise young breast cancer patients on fertility issues. Counseling of patients and their families might improve their understanding about the influence of such treatment on fertility and ensure effective FP. There are several FP methods that can be selected before beginning treatment, and these methods have both advantages and disadvantages. Young adults with breast cancer who want to bear children in the future must be provided with FP counseling, in addition to advice about breast cancer treatment and prognosis.
Literature
1.
go back to reference Institute of Medicine and National Research Council. From cancer patient to cancer survivor. USA: The National Academies Press; 2006. Institute of Medicine and National Research Council. From cancer patient to cancer survivor. USA: The National Academies Press; 2006.
2.
go back to reference Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29.PubMed Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29.PubMed
3.
go back to reference Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34(5):632–40.PubMedCrossRef Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, et al. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998;34(5):632–40.PubMedCrossRef
4.
go back to reference Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126–32.PubMedCrossRef Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126–32.PubMedCrossRef
5.
go back to reference Okanami Y, Ito Y, Watanabe C, Iijima K, Iwase T, Tokudome N, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–8.PubMedCrossRef Okanami Y, Ito Y, Watanabe C, Iijima K, Iwase T, Tokudome N, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–8.PubMedCrossRef
6.
go back to reference Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96:1808–16.PubMedCrossRefPubMedCentral Lutchman Singh K, Muttukrishna S, Stein RC, McGarrigle HH, Patel A, Parikh B, et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007;96:1808–16.PubMedCrossRefPubMedCentral
7.
go back to reference Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116:592–9.PubMedCrossRefPubMedCentral Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116:592–9.PubMedCrossRefPubMedCentral
8.
go back to reference Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on FP in cancer patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRef Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on FP in cancer patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRef
9.
go back to reference Zevine J, Canada A, Stern CJ. FP in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831–41.CrossRef Zevine J, Canada A, Stern CJ. FP in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831–41.CrossRef
10.
go back to reference Kubo A, Koido K, Sawada M, Ryushima Y, Shimizu C, Kato T, et al. Survey on oncologists-provided information on treatment-related infertility to breast cancer patients. Gan To Kagaku Ryoho. 2012;39(3):399–403 (in Japanese). Kubo A, Koido K, Sawada M, Ryushima Y, Shimizu C, Kato T, et al. Survey on oncologists-provided information on treatment-related infertility to breast cancer patients. Gan To Kagaku Ryoho. 2012;39(3):399–403 (in Japanese).
11.
go back to reference Shien T, Okada T, Tsuyumu Y, Emi Y, Nishiyama K, Masumura K, et al. Active counseling about fertility preserving for breast cancer patients receiving systemic therapy. Jpn J Breast Cancer. 2012;27(3):313–20. Shien T, Okada T, Tsuyumu Y, Emi Y, Nishiyama K, Masumura K, et al. Active counseling about fertility preserving for breast cancer patients receiving systemic therapy. Jpn J Breast Cancer. 2012;27(3):313–20.
12.
go back to reference Shimizu C, Bando H, Kato T, Mizota Y, Yamamoto S, Fujiwara Y. Physicians’ knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer. 2012 (Epub ahead of print). Shimizu C, Bando H, Kato T, Mizota Y, Yamamoto S, Fujiwara Y. Physicians’ knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer. 2012 (Epub ahead of print).
13.
go back to reference Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer–an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7.PubMedCrossRef Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer–an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7.PubMedCrossRef
14.
go back to reference Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229–39.PubMedCrossRef Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig. 1999;6(5):229–39.PubMedCrossRef
15.
go back to reference Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–41.PubMedCrossRef Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334–41.PubMedCrossRef
16.
go back to reference Japan Breast Cancer Society. Clinical practice guideline for breast cancer, systemic therapy. Tokyo: Kanehara; 2010 (in Japanese). Japan Breast Cancer Society. Clinical practice guideline for breast cancer, systemic therapy. Tokyo: Kanehara; 2010 (in Japanese).
17.
18.
go back to reference Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18(6):769–76.PubMedCrossRef Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18(6):769–76.PubMedCrossRef
19.
go back to reference Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand. 2004;83(12):1104–11.PubMedCrossRef Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand. 2004;83(12):1104–11.PubMedCrossRef
20.
go back to reference Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the two sister study. J Natl Cancer Inst. 2012;104(13):1021–7.PubMedCrossRefPubMedCentral Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the two sister study. J Natl Cancer Inst. 2012;104(13):1021–7.PubMedCrossRefPubMedCentral
21.
go back to reference Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124(1):13–26.PubMedCrossRef Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat. 2010;124(1):13–26.PubMedCrossRef
22.
go back to reference Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–79. Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–79.
23.
go back to reference Cooley A, Matthews L, Zelivianski S, Hardy A, Jeruss JS. Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro. Hum Reprod. 2012;27(1):146–52.PubMedCrossRefPubMedCentral Cooley A, Matthews L, Zelivianski S, Hardy A, Jeruss JS. Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro. Hum Reprod. 2012;27(1):146–52.PubMedCrossRefPubMedCentral
24.
go back to reference Boukaidi SA, Cooley A, Hardy A, Matthews L, Zelivianski S, Jeruss JS. Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro. Fertil Steril. 2012;97(2):440–4.PubMedCrossRefPubMedCentral Boukaidi SA, Cooley A, Hardy A, Matthews L, Zelivianski S, Jeruss JS. Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro. Fertil Steril. 2012;97(2):440–4.PubMedCrossRefPubMedCentral
26.
go back to reference Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–10.PubMedCrossRef Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–10.PubMedCrossRef
27.
go back to reference Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.PubMedCrossRef Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.PubMedCrossRef
Metadata
Title
Fertility preservation in breast cancer patients
Authors
Tadahiko Shien
Mikiya Nakatsuka
Hiroyoshi Doihara
Publication date
01-11-2014
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0463-5

Other articles of this Issue 6/2014

Breast Cancer 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine